Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saruparib - AstraZeneca

Next Previous
Drug Profile

Saruparib - AstraZeneca

Alternative Names: AZD-5305

Latest Information Update: 29 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Amides; Antineoplastics; Naphthyridines; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Prostate cancer
  • Phase II Pancreatic cancer; Solid tumours
  • Phase I/II Ovarian cancer

Most Recent Events

  • 17 Jul 2026 AstraZeneca plans a phase III EvoPAR-PR05 trial for Prostate cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (PO) in October 2026 (NCT07711002)
  • 15 Jun 2026 AstraZeneca completes a phase-I trial in Prostate cancer (Combination therapy, Monotherapy, First-line therapy) in Netherlands, Spain, United Kingdom, USA (PO) (NCT05938270)
  • 22 Apr 2026 Pharmacodynamics data from preclinical trial in Gastric cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top